Uterine Fibroids Clinical Landscape Report 2026: Trials, Readouts and White Space

Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.

Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.

Executive view

Uterine Fibroids remains an active clinical development field. The strongest programs are pairing biologically differentiated interventions with patient-centered outcomes, less burdensome delivery and longer evidence windows. The PatSnap evidence set used here contains 337 matched trial records and 73 indexed result records before the decision-focused sample below was selected.

How PatSnap MCP built this report

The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.

Trial landscape table

The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.

What indexed results say

• A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy (Phase 3): the indexed record reports -; Contraceptive Efficacy of Relugolix Combination Therapy as Assessed by the At-Risk Pearl Index (PI) = 1.27 Pregnancies per 100 woman-years (95% Confidence Interval, 0.55 - 2.50); -.
• Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study (Phase 3): the indexed record reports AE = hot flushes; AE = hot flushes; AE = hot flushes.
• Intra-Arterial Dexamethasone for the Alleviation of Pain and Postembolization Syndrome Following Uterine Artery Embolization (Phase 3): the indexed record reports Preprocedural(Mean) = 0.8 score on a scale (Standard Deviation, 1.5); -; -.

Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.

Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.

Asset and sponsor context

PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Nalbuphine Hydrochloride (Approved; κ opioid receptor x μ opioid receptor), Cyclobenzaprine hydrochloride (Approved; 5-HT2A receptor x ADRA2 x H1 receptor). Company & Deal Intelligence records identify sponsor context for Obstetrics and Gynecology Hospital of Fudan University, Christiana Care Health Services, Inc., Sheikh Shakhbout Medical City. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.

Where the white space is

1. Endpoints that capture daily function and treatment burden alongside biological change.
2. Long-duration comparisons against current procedural or pharmacologic standards.
3. Evidence across diverse ages, disease stages and reproductive contexts.
4. Delivery approaches that improve persistence without sacrificing safety.

Strategic implications

For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.

What to monitor next

Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.

Bottom line

Uterine Fibroids has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.